PanTera, a Belgian joint venture established by IBA and SCK CEN to secure large-scale production of alpha-emitting radioisotopes, has signed a capacity reservation agreement with Bayer for the supply of actinium-225 starting in the second half of 2024.
In 2024, PanTera will seek to increasing production of Ac-225 for clinical trial needs, and will develop a large-scale, state-of-the-art production facility to address growing global demand.
“PanTera’s emerging ability to start supplying Ac- 225 this year will allow research and clinical trials in this domain to advance,” said PanTera CEO Sven Van den Berghe. “The combined expertise and technology from SCK CEN and IBA places PanTera in a unique position to become the go-to global supplier of Ac-225 for (pre-)clinical trials and commercial use. PanTera is committed to supporting the pharmaceutical industry by scaling up production to meet the significant global demand for targeted radiopharma-based therapeutics in the fight against cancer.”
Image: PanTera's actinium-225 production facility (courtesy of PanTera)
